Provides for the proper packaging and labeling of pharmaceutical drugs; creates penalties for intentional fraudulent replacement, packaging, and labeling of such drugs; provides for better consumer protection.
Summary
Bill S01862 aims to amend the General Business Law in New York to enhance the integrity and safety of pharmaceutical drugs. It introduces penalties for individuals who engage in fraudulent practices related to the labeling, packaging, or sale of pharmaceutical drugs. Specifically, the bill criminalizes actions such as placing false descriptions on drug packaging, selling drugs with misleading labels, and concealing the origin of pharmaceutical products. The bill also empowers the Attorney General to seek injunctions against violators and impose civil penalties for each infraction.
Impact
If enacted, this bill will strengthen consumer protection laws regarding pharmaceutical drugs in New York. It will create a legal framework to penalize deceptive practices in the pharmaceutical industry, thereby aiming to reduce the incidence of counterfeit or misrepresented drugs in the market. The bill's provisions will likely lead to increased scrutiny of pharmaceutical labeling and packaging, impacting manufacturers, distributors, and retailers in the state.
Sentiment
The sentiment surrounding Bill S01862 appears to be generally supportive, as it addresses critical issues of consumer safety and the integrity of pharmaceutical products. However, there may be concerns from industry stakeholders regarding the implications of increased regulatory oversight and potential penalties.
Contention
Notable points of contention may arise from pharmaceutical companies and distributors who could argue that the bill imposes excessive regulatory burdens and may inadvertently penalize legitimate businesses. Additionally, there may be discussions about the balance between consumer protection and the operational realities of the pharmaceutical industry.
Provides for the proper packaging and labeling of pharmaceutical drugs; creates penalties for intentional fraudulent replacement, packaging, and labeling of such drugs; provides for better consumer protection.
An Act to amend and reenact ยงยง 4.1-1600, 4.1-1602, and 4.1-1603 of the Code of Virginia, relating to medical cannabis program; product labels; delivery.